General Information of Drug Transporter (DT)
DT ID	DTD0015 Transporter Info
Gene Name	ABCC4
Protein Name	Multidrug resistance-associated protein 4
Gene ID	10257
UniProt ID	O15439
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs1059751
Site of GPD	chr13:95020696 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.4145/2076 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Tenofovir	Drug Info	HIV Infection	Correlated with the increased likelihood of kidney diseases in patients (compare with Allele A)		[ 1]
Tenofovir	N.A.	Kidney Disorder	Allele G is associated with increased likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele A.		[ 1]
Tenofovir	N.A.	Drug Toxicity	Allele G is associated with decreased likelihood of Drug Toxicity when treated with tenofovir in women with HIV Infections as compared to allele A.		[ 2]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Allele G is not associated with severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to allele A.		[ 3]
Tenofovir	N.A.	HIV Infectious Disease	Allele G is associated with decreased likelihood of Drug Toxicity when treated with tenofovir in women with HIV Infections as compared to allele A.		[ 2]
Tenofovir	N.A.	HIV Infectious Disease	Allele G is associated with increased likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele A.		[ 1]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Neutropenia	Genotypes AA + AG is associated with decreased concentrations of tenofovir in people with Hepatitis B, Chronic as compared to genotype GG.		[ 4]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	Individuals with the rs1059751 AA genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or GG genotypes. However, conflicting evidence has been reported. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.		[ 2]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	Individuals with the rs1059751 AG genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the GG genotype and an increased risk as compared to those with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.		[ 2]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	Individuals with the rs1059751 GG genotype and HIV may have an increased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or AA genotypes. However, conflicting evidence has been reported. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.		[ 2]
Genetic Polymorphism	rs11568658
Site of GPD	chr13:95210754 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	A=0.0517/259 (Global)
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Latanoprost	Drug Info	Open-Angle Glaucoma	Correlated with the decreased drug response in patients (compare with genotype CC)		[ 5]
Valganciclovir	Drug Info	Kidney Transplantation	Correlated with the increased neutropenia risk in patients (compare with genotype CC)		[ 6]
Valganciclovir	N.A.	Neutropenia	Genotype AC is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.		[ 6]
Latanoprost	N.A.	Neutropenia	Genotype AC is associated with decreased response to latanoprost in people with Glaucoma, Open-Angle as compared to genotype CC.		[ 5]
Latanoprost	N.A.	Open-angle Glaucoma	Genotype AC is associated with decreased response to latanoprost in people with Glaucoma, Open-Angle as compared to genotype CC.		[ 5]
Valganciclovir	N.A.	Kidney Transplantation	Genotype AC is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.		[ 6]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Mercaptopurine	N.A.	Mucositis	Genotype AA is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AC + CC.		[ 7]
Misoprostol	N.A.	Fever	Genotype AA is associated with increased likelihood of Fever when treated with misoprostol in women with Postpartum hemorrhage NOS or Therapeutic abortion as compared to genotypes AC + CC.		[ 8]
Latanoprost	N.A.	Open-angle Glaucoma	Patients with the AA genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.		[ 5]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	Allele C is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele A.		[ 9]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Mercaptopurine	N.A.	Leukopenia	Allele A is not associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 10]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Latanoprost	N.A.	Open-angle Glaucoma	Patients with the CC genotype and open-angle glaucoma may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.		[ 5]
Valganciclovir	N.A.	Kidney Transplantation	Patients with the CC genotype and kidney transplant may have decreased risk of neutropenia when treated with valganciclovir compared to patients with the AC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.		[ 6]
Genetic Polymorphism	rs1678387
Site of GPD	chr13:95065652 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.0978/490 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Bisphosphonates	Drug Info	Osteonecrosis	Correlated with the increased likelihood of osteonecrosis in patients (compare with allele C)		[ 11]
Bisphosphonates	N.A.	Osteonecrosis	Allele T is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele C.		[ 11]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Bisphosphonates	N.A.	Osteonecrosis	Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.		[ 11]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Bisphosphonates	N.A.	Osteonecrosis	Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.		[ 11]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Bisphosphonates	N.A.	Osteonecrosis	Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.		[ 11]
Genetic Polymorphism	rs16950650
Site of GPD	chr13:95123178 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0437/219 (Global)
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Irinotecan	Drug Info	Small Cell Carcinoma	Correlated with the decreased overall survival in patients (compare with genotype CC)		[ 12]
Cisplatin	Drug Info	Small Cell Carcinoma	Correlated with the decreased overall survival in patients (compare with genotype CC)		[ 12]
Cisplatin	N.A.	Mucositis	Genotype CT is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype CC.		[ 12]
Irinotecan	N.A.	Mucositis	Genotype CT is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype CC.		[ 12]
Cisplatin	N.A.	Small Cell Carcinoma	Genotype CT is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype CC.		[ 12]
Irinotecan	N.A.	Small Cell Carcinoma	Genotype CT is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype CC.		[ 12]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cisplatin	N.A.	Small Cell Carcinoma	Patients with the CC genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CT. Other genetic and clinical factors may also influence a patient's response.		[ 12]
Irinotecan	N.A.	Small Cell Carcinoma	Patients with the CC genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CT. Other genetic and clinical factors may also influence a patient's response.		[ 12]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cisplatin	N.A.	Small Cell Carcinoma	Patients with the TT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.		[ 12]
Irinotecan	N.A.	Small Cell Carcinoma	Patients with the TT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.		[ 12]
Genetic Polymorphism	rs17268282
Site of GPD	chr13:95273060 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>T
Minor Allele Frequency	T=0.0389/195 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Furosemide	Drug Info	Heart Failure	Correlated with the increased drug response in patients (compare with allele G)		[ 13]
Furosemide	N.A.	Neutropenia	Allele T is associated with increased response to furosemide in people with Heart Failure as compared to allele G.		[ 13]
Furosemide	N.A.	Heart Failure	Allele T is associated with increased response to furosemide in people with Heart Failure as compared to allele G.		[ 13]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Furosemide	N.A.	Heart Failure	Patients with the GG genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to furosemide.		[ 13]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Furosemide	N.A.	Heart Failure	Patients with the GT genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype, or greater weight loss as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.		[ 13]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Furosemide	N.A.	Heart Failure	Patients with the TT genotype and decompensated heart failure may have greater weight loss when treated with furosemide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.		[ 13]
Genetic Polymorphism	rs7317112
Site of GPD	chr13:95271269 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.3922/1964 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased mucositis risk in patients (compare with genotypes AG + GG)		[ 14]
Methotrexate	N.A.	Mucositis	Genotype AA is associated with increased risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 14]
Glucarpidase	N.A.	Nephrotoxicity	Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 AA genotype may be less likely to require glucarpidase treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.		[ 15]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype AA is associated with increased risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 14]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Kidney Disorder	Allele G is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 16]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Genotype GG is associated with increased clearance of methotrexate in children with Acute lymphoblastic leukemia as compared to genotypes AA + AG.		[ 17]
Glucarpidase	N.A.	Nephrotoxicity	Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 GG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.		[ 15]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.		[ 14]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Glucarpidase	N.A.	Nephrotoxicity	Genotypes AG + GG are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 15]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Glucarpidase	N.A.	Nephrotoxicity	Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 AG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.		[ 15]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the AG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.		[ 14]
Genetic Polymorphism	rs9561765
Site of GPD	chr13:95030989 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.1088/545 (Global)
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	Drug Info	Gastrointestinal Stromal Tumors	Correlated with the increased drug response in patients (compare with genotype AA)		[ 18]
Imatinib	N.A.	Kidney Disorder	Genotype AG is associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.		[ 18]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotype AG is associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.		[ 18]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the AA genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the AG genotype. Other genetic and clinical factors may also influence time to progression.		[ 18]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	No patients with the GG genotype were present in this study. However, patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression.		[ 18]
Genetic Polymorphism	rs9561778
Site of GPD	chr13:95061461 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	T=0.1633/818 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:         14 Drugs in Total
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased adverse drug reaction risk in patients (compare with allele G)		[ 19]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased adverse drug reaction risk in patients (compare with allele G)		[ 19]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased adverse drug reaction risk in patients (compare with allele G); Correlated with the increased gastrointestinal toxicity risk in patients (compare with allele G); Correlated with the increased severity of neutropenia in patients (compare with allele G)		[ 19]
Cyclophosphamide	N.A.	Nephrotoxicity	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.		[ 19]
Doxorubicin	N.A.	Nephrotoxicity	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.		[ 19]
Fluorouracil	N.A.	Nephrotoxicity	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.		[ 19]
Cyclophosphamide	N.A.	Neutropenia	Allele T is associated with increased severity of Neutropenia when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.		[ 19]
Cyclophosphamide	N.A.	Breast Neoplasms	Allele T is associated with increased risk of gastrointestinal toxicity when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.		[ 19]
Cyclophosphamide	N.A.	Drug Toxicity	Allele T is associated with increased risk of gastrointestinal toxicity when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.		[ 19]
Cyclophosphamide	N.A.	Neoplasms	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.		[ 19]
Doxorubicin	N.A.	Breast Neoplasms	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.		[ 19]
Doxorubicin	N.A.	Neoplasms	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.		[ 19]
Fluorouracil	N.A.	Breast Neoplasms	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.		[ 19]
Fluorouracil	N.A.	Neoplasms	Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.		[ 19]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Cyclophosphamide	N.A.	Toxic Liver Disease	Genotype GG is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes GT + TT.		[ 20]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.		[ 19]
Cyclophosphamide	N.A.	Drug Toxicity	Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.		[ 19]
Cyclophosphamide	N.A.	Neoplasms	Patients with the rs9561778 GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the rs9561778 GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Doxorubicin	N.A.	Neoplasms	Patients with the rs9561778 GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the rs9561778 GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Fluorouracil	N.A.	Neoplasms	Patients with the rs9561778 GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.		[ 19]
Cyclophosphamide	N.A.	Drug Toxicity	Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.		[ 19]
Cyclophosphamide	N.A.	Neoplasms	Patients with the rs9561778 GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the rs9561778 GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Doxorubicin	N.A.	Neoplasms	Patients with the rs9561778 GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the rs9561778 GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Fluorouracil	N.A.	Neoplasms	Patients with the rs9561778 GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.		[ 19]
Cyclophosphamide	N.A.	Drug Toxicity	Patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.		[ 19]
Cyclophosphamide	N.A.	Neoplasms	Patients with the rs9561778 TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the rs9561778 TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Doxorubicin	N.A.	Neoplasms	Patients with the rs9561778 TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the rs9561778 TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Fluorouracil	N.A.	Neoplasms	Patients with the rs9561778 TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.		[ 19]
Genetic Polymorphism	rs1751034
Site of GPD	chr13:95062722 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.2057/1030 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Tenofovir	Drug Info	HIV Infection	Correlated with the increased drug renal clearance, and lower the total area under the plasma concentration-time curve (AUC) in patients (compare with genotypes CC + CT)		[ 21]
Tenofovir	N.A.	Neutropenia	Genotype TT is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotypes CC + CT.		[ 22]
Tenofovir	N.A.	Mucositis	Genotype TT is associated with decreased clearance of tenofovir in people with HIV Infections as compared to genotypes CC + CT.		[ 23]
Tenofovir	N.A.	Mucositis	Genotype TT is associated with increased tenofovir renal clearance, and lower AUC when treated with tenofovir as compared to genotypes CC + CT.		[ 21]
Tenofovir	N.A.	HIV Infectious Disease	Genotype TT is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotypes CC + CT.		[ 22]
Tenofovir	N.A.	HIV Infectious Disease	Genotype TT is associated with increased tenofovir renal clearance, and lower AUC when treated with tenofovir as compared to genotypes CC + CT.		[ 21]
Tenofovir	N.A.	HIV Infectious Disease	Genotype TT is associated with decreased clearance of tenofovir in people with HIV Infections as compared to genotypes CC + CT.		[ 23]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Tenofovir	Drug Info	HIV Infection	Correlated with the increased intracellular tenofovir diphosphate (tFV-DP) concentrations in patients (compare with Genotype TT)		[ 24]
Tenofovir	N.A.	Mucositis	Genotypes CC + CT are associated with increased intracellular tenofovir diphosphate (TFV-DP) concentrations when treated with tenofovir in people with HIV Infections as compared to genotype TT.		[ 24]
Tenofovir	N.A.	Mucositis	Genotypes CC + CT is not associated with concentrations of tenofovir in people with HIV Infections as compared to genotype TT.		[ 25]
Tenofovir	N.A.	HIV Infectious Disease	Genotypes CC + CT are associated with increased intracellular tenofovir diphosphate (TFV-DP) concentrations when treated with tenofovir in people with HIV Infections as compared to genotype TT.		[ 24]
Tenofovir	N.A.	HIV Infectious Disease	Genotypes CC + CT is not associated with concentrations of tenofovir in people with HIV Infections as compared to genotype TT.		[ 25]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Tenofovir	N.A.	Mucositis	Allele T is not associated with clearance of tenofovir in people with HIV Infections as compared to allele C.		[ 26]
Tenofovir	N.A.	HIV Infectious Disease	Allele T is not associated with clearance of tenofovir in people with HIV Infections as compared to allele C.		[ 26]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	Allele C is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele T.		[ 9]
Tenofovir	N.A.	Leukopenia	Allele C is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele T.		[ 28]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Allele C is not associated with severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to allele T.		[ 3]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no significant association between the rs1751034 CC genotype and concentrations of tenofovir. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentrations.		[ 22]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no significant association between the rs1751034 CT genotype and concentrations of tenofovir. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentrations.		[ 22]
Genetic Polymorphism	rs3742106
Site of GPD	chr13:95021537 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	C=0.4149/2078 (Global)
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Tenofovir	Drug Info	HIV Infection	Correlated with the increased drug concentrations in patients (compare with genotype AA)		[ 25]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Genotypes AC + CC are associated with increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate in people with HIV Infections as compared to genotype AA.		[ 22]
Tenofovir	N.A.	Neutropenia	Genotypes AC + CC are associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.		[ 22]
Tenofovir	N.A.	Mucositis	Genotypes AC + CC is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.		[ 25]
Tenofovir	N.A.	HIV Infectious Disease	Genotypes AC + CC are associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.		[ 22]
Tenofovir	N.A.	HIV Infectious Disease	Genotypes AC + CC is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.		[ 25]
Tenofovir Disoproxil Fumarate	N.A.	HIV Infectious Disease	Genotypes AC + CC are associated with increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate in people with HIV Infections as compared to genotype AA.		[ 22]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Valganciclovir	N.A.	Neutropenia	Genotype CC is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype AA.		[ 6]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the rs3742106 CC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.		[ 22]
Tenofovir Disoproxil Fumarate	N.A.	HIV Infectious Disease	Patients with HIV and the rs3742106 CC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 22]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Patients with HIV and the rs3742106 CC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 22]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Valganciclovir	N.A.	Neutropenia	Genotype AC is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype AA.		[ 6]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the rs3742106 AC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.		[ 22]
Tenofovir Disoproxil Fumarate	N.A.	HIV Infectious Disease	Patients with HIV and the rs3742106 AC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 22]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Patients with HIV and the rs3742106 AC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 22]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tenofovir	N.A.	Mucositis	Allele C is not associated with clearance of tenofovir in people with HIV Infections as compared to allele A.		[ 26]
Tenofovir	N.A.	Leukopenia	Allele C is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele A.		[ 27]
Tenofovir	N.A.	HIV Infectious Disease	Allele C is not associated with clearance of tenofovir in people with HIV Infections as compared to allele A.		[ 26]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	Patients with the rs3742106 AA genotype may have decreased plasma concentrations of tenofovir in people with HIV as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.		[ 22]
Tenofovir Disoproxil Fumarate	N.A.	HIV Infectious Disease	Patients with HIV and the rs3742106 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 22]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Patients with HIV and the rs3742106 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 22]
Genetic Polymorphism	rs3765534
Site of GPD	chr13:95163161 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0312/156 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Mercaptopurine	Drug Info	Inflammatory Bowel Diseases	Correlated with the increased sensitivity to drug in nA18967 cells (compare with genotype CC)		[ 28]
Mercaptopurine	N.A.	Neutropenia	Genotype TT is associated with increased sensitivity to mercaptopurine in NA18967 cells as compared to genotype CC.		[ 28]
Mercaptopurine	N.A.	Mucositis	Genotype TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 7]
Azathioprine	N.A.	Inflammatory Bowel Diseases	Genotype TT is associated with increased sensitivity to mercaptopurine in NA18967 cells as compared to genotype CC.		[ 28]
Mercaptopurine	N.A.	Inflammatory Bowel Diseases	Genotype TT is associated with increased sensitivity to mercaptopurine in NA18967 cells as compared to genotype CC.		[ 28]
Azathioprine	N.A.	Inflammatory Bowel Diseases	Patients with the TT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.		[ 30]
Mercaptopurine	N.A.	Inflammatory Bowel Diseases	Patients with the TT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.		[ 30]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Azathioprine	Drug Info	Inflammatory Bowel Diseases	Correlated with the increased likelihood of leukopenia in patients (compare with genotype CC)		[ 29]
Mercaptopurine	Drug Info	Inflammatory Bowel Diseases	Correlated with the increased likelihood of leukopenia in patients (compare with genotype CC)		[ 29]
Azathioprine	N.A.	Leukopenia	Genotypes CT + TT are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.		[ 29]
Mercaptopurine	N.A.	Leukopenia	Genotypes CT + TT are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.		[ 29]
Azathioprine	N.A.	Inflammatory Bowel Diseases	Genotypes CT + TT are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.		[ 29]
Mercaptopurine	N.A.	Inflammatory Bowel Diseases	Genotypes CT + TT are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.		[ 29]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Mercaptopurine	N.A.	Opioid-related Disorders	Genotype CC is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.		[ 30]
Methotrexate	N.A.	Opioid-related Disorders	Genotype CC is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.		[ 30]
Azathioprine	N.A.	Inflammatory Bowel Diseases	Patients with the CC genotype and inflammatory bowel disease may have a decreased risk for leukopenia when treated with thiopurines as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.		[ 29]
Mercaptopurine	N.A.	Inflammatory Bowel Diseases	Patients with the CC genotype and inflammatory bowel disease may have a decreased risk for leukopenia when treated with thiopurines as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.		[ 29]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Mercaptopurine	N.A.	Leukopenia	Allele T is associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 10]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Azathioprine	N.A.	Inflammatory Bowel Diseases	Patients with the CT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.		[ 29]
Mercaptopurine	N.A.	Inflammatory Bowel Diseases	Patients with the CT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.		[ 29]
Genetic Polymorphism	rs9516519
Site of GPD	chr13:95020203 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	G=0.0591/296 (Global)
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	Drug Info	Acute B-Cell Leukemia	Correlated with the decreased drug plasma level in patients (compare with Genotype TT); Correlated with the decreased toxicity risk in patients (compare with Genotype TT)		[ 31]
Methotrexate	N.A.	Neutropenia	Genotypes GG + GT are associated with decreased plasma level when exposed to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 31]
Methotrexate	N.A.	Burkitt Lymphoma	Genotypes GG + GT are associated with decreased risk of toxicity when exposed to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 31]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele G is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 32]
Methotrexate	N.A.	Drug Toxicity	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 33]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the GG genotype who are treated with methotrexate may have decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 31]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the GT genotype who are treated with methotrexate may have decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 31]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the TT genotype who are treated with methotrexate may have increased risk for toxicity and increased plasma level as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.		[ 31]
Genetic Polymorphism	rs11568644
Site of GPD	chr13:95053126 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.9970/1973 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
17beta-estradiol Glucuronide	N.A.	Opioid-related Disorders	Allele A is associated with decreased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele G.		[ 34]
Genetic Polymorphism	rs200858900
Site of GPD	chr13:95186874 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
17beta-estradiol Glucuronide	N.A.	Opioid-related Disorders	Allele T is associated with decreased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele C.		[ 34]
Genetic Polymorphism	rs11568681
Site of GPD	chr13:95301263 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>T
Minor Allele Frequency	G=0.9810/1941 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
17beta-estradiol Glucuronide	N.A.	Opioid-related Disorders	Allele T is associated with increased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele G.		[ 34]
Genetic Polymorphism	rs142211148
Site of GPD	chr13:95178045 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=1.0000/1979 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
17beta-estradiol Glucuronide	N.A.	Opioid-related Disorders	Allele T is associated with increased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele C.		[ 34]
Genetic Polymorphism	rs1557070
Site of GPD	chr13:95186749 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9130/1806 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Opioid-related Disorders	Allele A is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 9]
Genetic Polymorphism	rs868853
Site of GPD	chr13:95302822 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.1800/356 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele C is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 32]
Genetic Polymorphism	rs2274407
Site of GPD	chr13:95206781 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	C=0.8530/1688 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Methotrexate	N.A.	Neutropenia	Allele A is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 32]
Methotrexate	N.A.	Mucositis	Allele A is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 36]
Methotrexate	N.A.	Kidney Disorder	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 37]
Mercaptopurine	N.A.	Leukopenia	Allele A is not associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 10]
Efavirenz	N.A.	Thrombocytopenia	Allele A is associated with risk of hyperhidrosis when treated with efavirenz in people with HIV as compared to genotype G.		[ 39]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Valganciclovir	N.A.	Neutropenia	Genotype AC is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.		[ 6]
Antineoplastic Agents	N.A.	Thrombocytopenia	Genotype AC is associated with increased severity of Thrombocytopenia when treated with antineoplastic agents, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Mercaptopurine	N.A.	Thrombocytopenia	Genotype AC is associated with increased severity of Thrombocytopenia when treated with antineoplastic agents, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Methotrexate	N.A.	Thrombocytopenia	Genotype AC is associated with increased severity of Thrombocytopenia when treated with antineoplastic agents, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Antineoplastic Agents	N.A.	Thrombocytopenia	Genotype AC is associated with decreased event free survival when treated with antineoplastic agents, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Mercaptopurine	N.A.	Thrombocytopenia	Genotype AC is associated with decreased event free survival when treated with antineoplastic agents, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Methotrexate	N.A.	Thrombocytopenia	Genotype AC is associated with decreased event free survival when treated with antineoplastic agents, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Mercaptopurine	N.A.	Mucositis	Genotype AA is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AC + CC.		[ 7]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Mercaptopurine	N.A.	Leukopenia	Genotype CC is associated with increased risk of Leukopenia and Neutropenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.		[ 39]
Mercaptopurine	N.A.	Neutropenia	Genotype CC is associated with increased risk of Leukopenia and Neutropenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.		[ 39]
Methotrexate	N.A.	Leukopenia	Genotype CC is associated with increased risk of Leukopenia and Neutropenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.		[ 39]
Methotrexate	N.A.	Neutropenia	Genotype CC is associated with increased risk of Leukopenia and Neutropenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.		[ 39]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	Allele T is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV as compared to allele G.		[ 9]
Genetic Polymorphism	rs11568695
Site of GPD	chr13:95044286 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.9500/1880 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Indinavir	N.A.	Neutropenia	Allele T is associated with increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment when treated with indinavir, lamivudine and zidovudine in people with HIV Infections as compared to genotype CC.		[ 40]
Lamivudine	N.A.	Neutropenia	Allele T is associated with increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment when treated with indinavir, lamivudine and zidovudine in people with HIV Infections as compared to genotype CC.		[ 40]
Zidovudine	N.A.	Neutropenia	Allele T is associated with increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment when treated with indinavir, lamivudine and zidovudine in people with HIV Infections as compared to genotype CC.		[ 40]
Tenofovir	N.A.	Drug Toxicity	Allele T is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele C.		[ 9]
Zidovudine	N.A.	HIV Infectious Disease	Allele T is associated with increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment when treated with indinavir, lamivudine and zidovudine in people with HIV Infections as compared to genotype CC.		[ 40]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Zidovudine	N.A.	HIV Infectious Disease	Patients with the CC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have a decreased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.		[ 40]
Genotype TC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Zidovudine	N.A.	HIV Infectious Disease	Patients with the TC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.		[ 40]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Zidovudine	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.		[ 40]
Genetic Polymorphism	rs146708960
Site of GPD	chr13:95161318 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Mercaptopurine	N.A.	Neutropenia	Genotype CT is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 30]
Methotrexate	N.A.	Neutropenia	Genotype CT is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 30]
Genetic Polymorphism	rs11568668
Site of GPD	chr13:95186786 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Latanoprost	N.A.	Mucositis	Genotype TT is not associated with response to latanoprost in people with Glaucoma, Open-Angle as compared to genotypes CC + CT.		[ 5]
Genetic Polymorphism	rs899494
Site of GPD	chr13:95209550 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.1920/379 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Fanconi Renotubular Syndrome	Allele G is not associated with increased risk of Fanconi Syndrome when treated with tenofovir in people with HIV Infections as compared to allele A.		[ 41]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	Allele A is associated with increased likelihood of Drug Toxicity when treated with tenofovir in women with HIV Infections as compared to allele G.		[ 2]
Tenofovir	N.A.	Drug Toxicity	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 9]
Tenofovir	N.A.	Leukopenia	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 27]
Tenofovir	N.A.	Drug Toxicity	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 9]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 9]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is associated with increased likelihood of Drug Toxicity when treated with tenofovir in women with HIV Infections as compared to allele G.		[ 2]
Tenofovir	N.A.	Drug Toxicity	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 27]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 27]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	Genotypes AA + AG is not associated with increased discontinuation of tenofovir in people with HIV Infections as compared to genotype GG.		[ 42]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	The current evidence base suggests that there is no significant association between the rs899494 AA genotype and likelihood of developing renal proximal tubulopathy when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing renal proximal tubulopathy when treated with tenofovir.		[ 9]
Tenofovir	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no significant association between the rs899494 AA genotype and likelihood of developing renal proximal tubulopathy when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing renal proximal tubulopathy when treated with tenofovir.		[ 9]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	The current evidence base suggests that there is no significant association between the rs899494 AG genotype and likelihood of developing renal proximal tubulopathy when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing renal proximal tubulopathy when treated with tenofovir.		[ 9]
Tenofovir	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no significant association between the rs899494 AG genotype and likelihood of developing renal proximal tubulopathy when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing renal proximal tubulopathy when treated with tenofovir.		[ 9]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	The current evidence base suggests that there is no significant association between the rs899494 GG genotype and likelihood of developing renal proximal tubulopathy when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing renal proximal tubulopathy when treated with tenofovir.		[ 9]
Tenofovir	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no significant association between the rs899494 GG genotype and likelihood of developing renal proximal tubulopathy when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing renal proximal tubulopathy when treated with tenofovir.		[ 9]
Genetic Polymorphism	rs2274405
Site of GPD	chr13:95206724 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.3720/736 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	Allele T is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele C.		[ 9]
Genetic Polymorphism	rs2274406
Site of GPD	chr13:95206742 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.4860/961 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	Allele T is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele C.		[ 9]
Genetic Polymorphism	rs11568655
Site of GPD	chr13:95062760 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.9710/1921 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Drug Toxicity	Allele G is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele A.		[ 9]
Genetic Polymorphism	rs7322318
Site of GPD	chr13:95271434 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.5840/1155 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele C is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele T.		[ 43]
Genetic Polymorphism	rs4148472
Site of GPD	chr13:95210619 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	G=0.7740/1531 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele A is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele G.		[ 43]
Genetic Polymorphism	rs4771904
Site of GPD	chr13:95024288 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.4060/803 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele G.		[ 43]
Genetic Polymorphism	rs1678396
Site of GPD	chr13:95156694 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.5570/1102 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele G is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele A.		[ 43]
Genetic Polymorphism	rs17268122
Site of GPD	chr13:95192240 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.9120/1804 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Mercaptopurine	N.A.	Thrombocytopenia	Allele T is associated with TPMT activity when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 44]
Thioguanine	N.A.	Thrombocytopenia	Allele T is associated with TPMT activity when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 44]
Genetic Polymorphism	rs9556455
Site of GPD	chr13:95045162 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.8580/1697 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Thioguanine	N.A.	Thrombocytopenia	Allele A is associated with 6-thioguanine and 6-thioguanine nucleotide levels when treated with thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 44]
References
1	A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection. PLoS One. 2016 Jan 25;11(1):e0147724.
2	Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans. Pharmacogenet Genomics. 2023 Jul 01;33(5):91-100.
3	Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. Pharmacogenomics J. 2020 Apr;20(2):202-212.
4	Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?. Biomed Pharmacother. 2024 Jun;175:116678.
5	Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients. Eur J Clin Pharmacol. 2015 Jan;71(1):43-50.
6	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacol Res. 2016 Sep;111:501-508.
7	Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015 Aug;15(4):380-4.
8	Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. Pharmacogenomics. 2015;16(9):919-28.
9	Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006 Dec 1;194(11):1481-91.
10	Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2018 Apr;18(2):275-280.
11	Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist. 2012;17(2):279-87.
12	A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy. Pharmacogenomics J. 2014 Feb;14(1):20-7.
13	A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. Pharmacogenomics J. 2017 Mar;17(2):192-200.
14	Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2015 Jun;15(3):248-54.
15	Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. Pediatr Blood Cancer. 2021 Aug;68(8):e29036.
16	Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy. 2023 Mar;43(3):205-214.
17	The Role of Candidate Polymorphisms in Drug Transporter Genes on High-Dose Methotrexate in the Consolidation Phase of the AIEOP-BFM ALL 2009 Protocol. Clin Transl Sci. 2025 Feb;18(2):e70136.
18	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res. 2013 Feb;68(1):1-6.
19	Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet. 2009 Oct;54(10):564-71.
20	The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. Clin Immunol. 2015 Oct;160(2):342-8.
21	The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008 Feb;83(2):265-72.
22	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. Pharmacogenomics J. 2021 Oct;21(5):586-593.
23	Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients. Pharmacogenomics. 2017 Nov;18(16):1481-1490.
24	Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):298-303.
25	Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. Antimicrob Agents Chemother. 2015;59(6):3240-5.
26	Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. Pharmacogenet Genomics. 2023 Jun 01;33(4):79-87.
27	Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009 Jun 1;48(11):e108-16.
28	Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 2008 Jul 1;68(13):4983-9.
29	The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2010 Oct;45(10):1014-21.
30	SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy. J Pediatr Hematol Oncol. 2018 Jul;40(5):e289-e294.
31	Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2013 Feb;23(2):53-61.
32	Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One. 2014 Jan 3;9(1):e82681.
33	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. J Clin Pharmacol. 2018 Dec;58(12):1541-1549.
34	In-vitro characterization of coding variants with predicted functional implications in the efflux transporter multidrug resistance protein 4 (MRP4, ABCC4). Pharmacogenet Genomics. 2022 Apr 01;32(3):111-116.
35	Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study. J Clin Pharm Ther. 2021 Dec;46(6):1557-1563.
36	Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28858.
37	Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics. 2013 Jul;14(10):1167-78.
38	Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
39	Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015;16(10):1119-34.
40	Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 Aug 01;42(4):441-9.
41	A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet Genomics. 2015 Feb;25(2):82-92.
42	Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis. 2011 Jan 15;203(2):246-57.
43	Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis. J Clin Pharmacol. 2020 Mar;60(3):361-368.
44	Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics. 2014 Mar;15(4):433-47.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.